Immune Checkpoint Inhibitor-Associated Uveitis: Predictors and Survival Impact
Leila Chew, Jeffrey Feng, Elizabeth Hutchins, Ashley Stein-Merlob, Eric H. Yang, Melissa G. Lechner, Edmund Tsui
原始摘要（英文原文）· Original abstract
In 5966 patients treated with immune checkpoint inhibitors, uveitis was rare (0.49%) but linked to combination therapy, greater cumulative exposure, and prior uveitis. Uveitis occurrence was correlated with longer survival, suggesting heightened systemic immune activation.